Does inhibition of P-glycoprotein lead to drug-drug interactions?

Toxicology Letters

Volumn 156, Issue 3, 2005, Pages 319-329

  Balayssac, David ^a   Authier, Nicolas ^a   Cayre, Anne ^b   Coudore, François ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b CENTRE JEAN PERRIN   (France)

Author keywords

Absorption; Distribution.; Drug drug interaction; Excretion; Pgp; Pharmacokinetic

Indexed keywords

ASIMADOLINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERYTHROMYCIN; ETOPOSIDE; FELBAMATE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GRAMICIDIN; GRAMICIDIN D; GREPAFLOXACIN; ITRACONAZOLE; LAMOTRIGINE; LOPERAMIDE; MEVINOLIN; MITOMYCIN C; MITOXANTRONE; MORPHINE; PACLITAXEL; RIFAMPICIN; TAMOXIFEN; TOPOTECAN; UNINDEXED DRUG; VALINOMYCIN; VINBLASTINE; VINCRISTINE;

ABSORPTION; BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG IDENTIFICATION; DRUG TRANSPORT; DRUG UPTAKE; EFFUSION; NONHUMAN; PLACENTA; PRIORITY JOURNAL; SHORT SURVEY; STANDARD;

EID: 14844295815     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2004.12.008     Document Type: Review

References (94)

1. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398
2. S. Anuchapreeda, P. Leechanachai, M.M. Smith, S.V. Ambudkar, and P.N. Limtrakul Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells Biochem. Pharmacol. 64 2002 573 582
3. M. Arboix, O.G. Paz, T. Colombo, and M. D'Incalci Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis J. Pharmacol. Exp. Ther. 281 1997 1226 1230
4. B.J. Aungst P-glycoprotein secretory transport and other barriers to the oral delivery of anti-HIV drugs Adv. Drug. Deliv. Rev. 39 1999 105 116
5. M.A. Barrand, K.J. Robertson, and S.F. von Weikersthal Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta FEBS Lett. 374 1995 179 183
6. J. Bart, H.J. Groen, W.T. van der Graaf, H. Hollema, N.H. Hendrikse, W. Vaalburg, D.T. Sleijfer, and E.G. de Vries An oncological view on the blood-testis barrier Lancet Oncol. 3 2002 357 363
7. L. Becquemont, C. Verstuyft, R. Kerb, U. Brinkmann, M. Lebot, P. Jaillon, and C. Funck-Brentano Effect of grapefruit juice on digoxin pharmacokinetics in humans Clin. Pharmacol. Ther. 70 2001 311 316
8. W.T. Bellamy, Y.M. Peng, A. Odeleye, L. Ellsworth, M.J. Xu, T.M. Grogan, and R.S. Weinstein Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A Anticancer Drugs 6 1995 736 743
9. R.K. Bhardwaj, H. Glaeser, L. Becquemont, U. Klotz, S.K. Gupta, and M.F. Fromm Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 J. Pharmacol. Exp. Ther. 302 2002 645 650
10. A.L. Billson, J.B. Palmer, D.A. Walker, and J. Lowe Multidrug resistance gene (MDR 1) expression in neuro-axial tumours of children and young adults Brit. J. Neurosurg. 8 1994 585 591
11. L. Candussio, G. Decorti, E. Crivellato, M. Granzotto, A. Rosati, T. Giraldi, and F. Bartoli Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin Life Sci. 71 2002 3109 3119
12. M. Chishty, A. Reichel, J. Siva, N.J. Abbott, and D.J. Begley Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines J. Drug Target. 9 2001 223 228
13. E.F. Choo, B. Leake, C. Wandel, H. Imamura, A.J. Wood, G.R. Wilkinson, and R.B. Kim Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes Drug Metab. Dipos. 28 2000 655 660
14. T. Colombo, M. Zucchetti, and M. D'Incalci Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats J. Pharmacol. Exp. Ther. 269 1994 22 27
15. C. Cordon-Cardo, J.P. O'Brien, D. Casals, L. Rittman-Grauer, J.L. Biedler, M.R. Melamed, and J.R. Bertino Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc. Natl. Acad. Sci. U.S.A. 86 1989 695 698
16. C. Cordon-Cardo, J.P. O'Brien, J. Boccia, D. Casals, J.R. Bertino, and M.R. Melamed Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues J. Histochem. Cytochem. 38 1990 1277 1287
17. J.M. Croop, M. Raymond, D. Haber, A. Devault, R.J. Arceci, P. Gros, and D.E. Housman The three mouse multidrug resistance (MDR) genes are expressed in a tissue-specific manner in normal mouse tissues Mol. Cell. Biol. 9 1989 1346 1350
18. Y. Dan, H. Murakami, N. Koyabu, H. Ohtani, and Y. Sawada Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil J. Pharm. Pharmacol. 54 2002 729 733
19. S. Desrayaud, P. Guntz, J.M. Scherrmann, and M. Lemaire Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine Life Sci. 61 1997 153 163
20. R. Ding, Y. Tayrouz, K.D. Riedel, J. Burhenne, J. Weiss, G. Mikus, and W.E. Haefeli Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers Clin. Pharmacol. Ther. 76 2004 73 84
21. A.T. Fojo, K. Ueda, D.J. Slamon, D.G. Poplack, M.M. Gottesman, and I. Pastan Expression of a multidrug-resistance gene in human tumors and tissues Proc. Natl. Acad. Sci. U.S.A. 84 1987 265 269
22. B.C. Foster, M.S. Foster, S. Vandenhoek, A. Krantis, J.W. Budzinski, J.T. Arnason, K.D. Gallicano, and S. Choudri An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic J. Pharm. Pharm. Sci. 4 2001 176 184
23. M.F. Fromm, R.B. Kim, C.M. Stein, G.R. Wilkinson, and D.M. Roden Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 1999 552 557
24. P. Genne, B. Coudert, H. Pelletier, C. Girardot, F. Martin, and B. Chauffert Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance Anticancer Res. 9 1989 1655 1659
25. O. Gonzalez, T. Colombo, M. De Fusco, L. Imperatori, M. Zucchetti, and M. D'Incalci Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833 Cancer Chemother. Pharmacol. 36 1995 335 340
26. C.F. Higgins ABC transporters: from microorganisms to man Annu. Rev. Cell. Biol. 8 1992 67 113
27. G. Holcberg, O. Sapir, M. Tsadkin, M. Huleihel, S. Lazer, M. Katz, M. Mazor, and Z. Ben-Zvi Lack of interaction of digoxin and P-glycoprotein inhibitors, quinidine and verapamil in human placenta in vitro Eur. J. Obstet. Gynecol. Reprod. Biol. 109 2003 133 137
28. C.S. Hughes, S.L. Vaden, C.A. Manaugh, G.S. Price, and L.C. Hudson Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats J. Neurooncol. 37 1998 45 54
29. S. Ibrahim, J. Peggins, A. Knapton, T. Licht, and A. Aszalos Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation J. Pharmacol. Exp. Ther. 295 2000 1276 1283
30. S. Ibrahim, J. Peggins, A. Knapton, T. Licht, and A. Aszalos Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation Anticancer Res. 21 2001 847 856
31. L. Jette, G.F. Murphy, J.M. Leclerc, and R. Beliveau Interaction of drugs with P-glycoprotein in brain capillaries Biochem. Pharmacol. 50 1995 1701 1709
32. D.R. Johnson, R.A. Finch, Z.P. Lin, C.J. Zeiss, and A.C. Sartorelli The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice Cancer Res. 61 2001 1469 1476
33. J.W. Jonker, E. Wagenaar, L. Van Deemter, R. Gottschlich, H.M. Bender, J. Dasenbrock, and A.H. Schinkel Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgesic drug Brit. J. Pharmacol. 127 1999 43 50
34. R.L. Juliano, and V. Ling A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants Biochim. Biophys. Acta 455 1976 152 162
35. W. Kang, and M. Weiss Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin Pharm. Res. 18 2001 1535 1541
36. N. Kartner, J.R. Riordan, and V. Ling Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines Science 221 1983 1285 1288
37. S.W. Kim, H.Y. Kwon, D.W. Chi, J.H. Shim, J.D. Park, Y.H. Lee, S. Pyo, and D.K. Rhee Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3) Biochem. Pharmacol. 65 2003 75 82
38. G.R. Lankas, L.D. Wise, M.E. Cartwright, T. Pippert, and D.R. Umbenhauer Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice Reprod. Toxicol. 12 1998 457 463
39. S.P. Letrent, G.M. Pollack, K.R. Brouwer, and L.R. Brouwer Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat Drug Metab. Dipos. 27 1999 827 834
40. J.H. Lin Drug-drug interaction mediated by inhibition and induction of P-glycoprotein Adv. Drug. Deliv. Rev. 55 2003 53 81
41. A.F. List The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia Leukemia 10 1996 36 38
42. J. Lötsch, R. Schmidt, G. Vetter, H. Schmidt, E. Niederberger, G. Geisslinger, and I. Tegeder Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein J. Neurochem. 83 2002 241 248
43. M. Martin-Facklam, J. Burhenne, R. Ding, R. Fricker, G. Mikus, I. Walter-Sack, and W.E. Haefeli Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL Brit. J. Clin. Pharmacol. 53 2002 576 581
44. Y. Nakamura, S. Ikeda, T. Furukawa, T. Sumizawa, A. Tani, S. Akiyama, and Y. Nagata Function of P-glycoprotein expressed in placenta and mole Biochem. Biophys. Res. Commun. 235 1997 849 853
45. K.L. Napoli, M.E. Wang, S.M. Stepkowski, and B.D. Kahan Relative tissue distributions of cyclosporin and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions Ther. Drug Monit. 20 1998 123 133
46. M. Novotna, A. Libra, M. Kopecky, P. Pavek, Z. Fendrich, V. Semecky, and F. Staud P-glycoprotein expression and distribution in the rat placenta during pregnancy Reprod. Toxicol. 18 2004 785 792
47. R.P. Oude Elferink, R. Ottenhoff, M. van Wijland, C.M. Frijters, C. van Nieuwkerk, and A.K. Groen Uncoupling of biliary phospholipid and cholesterol secretion in mice with reduced expression of mdr2 P-glycoprotein J. Lipid Res. 37 1996 1065 1075
48. C. Pauli-Magnus, S. Rekersbrink, U. Klotz, and M.F. Fromm Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein Naunyn Schmiedebergs Arch. Pharmacol. 364 2001 551 557
49. A. Pohl, H. Lage, P. Muller, T. Pomorski, and A. Herrmann Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line Biochem. J. 365 2002 259 268
50. J.W. Polli, J.L. Jarrett, S.D. Studenberg, J.E. Humphreys, S.W. Dennis, K.R. Brouwer, and J.L. Woolley Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor Pharm. Res. 16 1999 1206 1212
51. H. Potschka, M. Fedrowitz, and W. Loscher P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain Neuroreport 12 2001 3557 3560
52. H. Potschka, and W. Loscher In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats Epilepsia 42 2001 1231 1240
53. H. Potschka, M. Fedrowitz, and W. Loscher P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats Neurosci. Lett. 327 2002 173 176
54. N. Romiti, R. Tongiani, F. Cervelli, and E. Chieli Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes Life Sci. 62 1998 2349 2358
55. A.J. Sadeque, C. Wandel, H. He, S. Shah, and A.J. Wood Increased drug delivery to the brain by P-glycoprotein inhibition Clin. Pharmacol. Ther. 68 2000 231 237
56. T. Saito, Z.J. Zhang, Y. Shibamori, T. Ohtsubo, I. Noda, T. Yamamoto, and H. Saito P-glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood-nerve barrier sites Neurosci. Lett. 232 1997 41 44
57. T. Saito, Z.J. Zhang, M. Tokuriki, T. Ohtsubo, Y. Shibamori, T. Yamamoto, and H. Saito Cyclosporin A inhibits the extrusion pump function of p-glycoprotein in the inner ear of mice treated with vinblastine and doxorubicin Brain Res. 901 2001 265 270
58. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, C.A. Mol, M.A. van der Valk, E.C. Robanus-Maandag, H.P. te Riele, A.J.M. Berns, and P. Borst Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 7 1994 491 502
59. A.H. Schinkel, E. Wagenaar, L. van Deemter, C.A. Mol, and P. Borst Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A J. Clin. Invest. 96 1995 1698 1705
60. A.H. Schinkel, and J.W. Jonker Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview Adv. Drug. Deliv. Rev. 55 2003 3 29
61. U.I. Schwarz, T. Gramatte, J. Krappweis, R. Oertel, and W. Kirch P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans Int. J. Clin. Pharmacol. Ther. 38 2000 161 167
62. B.E. Sipe, R.J. Jones, and G.H. Bokhart Rhabdomyolysis causing av blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction Ann. Pharmacother. 37 2003 808 811
63. J.W. Smit, M.T. Huisman, O. van Tellingen, H.R. Wiltshire, and A.H. Schinkel Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure J. Clin. Invest. 104 1999 1441 1447
64. A. Soldner, U. Christians, M. Susanto, V.J. Wacher, J.A. Silverman, and L.Z. Benet Grapefruit juice activates P-glycoprotein-mediated drug transport Pharm. Res. 16 1999 478 485
65. H. Spahn-Langguth, G. Baktir, A. Radschuweit, A. Okyar, B. Terhaag, P. Ader, A. Hanafy, and P. Langguth P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound Int. J. Clin. Pharmacol. Ther. 36 1998 16 24
66. H. Spahn-Langguth, and P. Langguth Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol Eur. J. Pharm. Sci. 12 2001 361 367
67. A. Sparreboom, J. van Asperen, U. Mayer, A.H. Schinkel, J.W. Smit, D.K. Meijer, P. Borst, W.J. Nooijen, J.H. Beijnen, and O. van Tellingen Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc. Natl. Acad. Sci. U.S.A. 94 1997 2031 2035
68. I.H. Stockley Drug Interaction 5th ed. 1999 Pharmaceutical Press pp. 1-14
69. T.R. Stouch, and O. Gudmundsson Progress in understanding the structure-activity relationships of P-glycoprotein Adv. Drug. Deliv. Rev. 54 2002 315 328
70. S.F. Su, and J.D. Huang Inhibition of the intestinal digoxin absorption and exsorption by quinidine Drug Metab. Dispos. 24 1996 142 147
71. H. Suzuki, and Y. Sugiyama Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine Eur. J. Pharm. Sci. 12 2000 3 12
72. H. Takanaga, A. Ohnishi, H. Matsuo, and Y. Sawada Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells Biol. Pharm. Bull. 21 1998 1062 1066
73. Y. Tayrouz, R. Ding, J. Burhenne, K.D. Riedel, J. Weiss, T. Hoppe-Tichy, W.E. Haefeli, and G. Mikus Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40 Clin. Pharmacol. Ther. 73 2003 397 405
74. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, and M.C. Willingham Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc. Natl. Acad. Sci. U.S.A. 84 1987 7735 7738
75. F. Thiebaut, T. Tsuruo, H. Hamada, M.M. Gottesman, I. Pastan, and M.C. Willingham Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein J. Histochem. Cytochem. 37 1989 159 164
76. K. Ueda, N. Okamura, M. Hirai, Y. Tanigawara, T. Saeki, N. Kioka, T. Komano, and R. Hori Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone J. Biol. Chem. 267 1992 24248 24252
77. F. Ushigome, H. Takanaga, H. Matsuo, S. Yanai, K. Tsukimori, H. Nakano, T. Uchiumi, T. Nakamura, M. Kuwano, H. Ohtani, and Y. Sawada Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein Eur. J. Pharmacol. 408 2000 1 10
78. J. van Asperen, A.H. Schinkel, J.H. Beijnen, W.J. Nooijen, P. Borst, and O. van Tellingen Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice J. Natl. Cancer Inst. 88 1996 994 999
79. J. van Asperen, O. van Tellingen, A. Sparreboom, A.H. Schinkel, P. Borst, W.J. Nooijen, and J.H. Beijnen Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833 Brit. J. Cancer 76 1997 1181 1183
80. J. van Asperen, O. van Tellingen, A.H. Schinkel, and J.H. Beijnen Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein J. Pharmacol. Exp. Ther. 289 1999 329 333
81. I.C. van der Sandt, R. Smolders, L. Nabulsi, K.P. Zuideveld, A.G. de Boer, and D.D. Breimer Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier Eur. J. Pharm. Sci. 14 2001 81 86
82. I.C. van der Sandt, P.J. Gaillard, H.H. Voorwinden, A.G. de Boer, and D.D. Breimer P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier Pharm. Res. 18 2001 587 592
83. H. Wakasugi, I. Yano, T. Ito, T. Hashida, T. Futami, R. Nohara, S. Sasayama, and K. Inui Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein Clin. Pharmacol. Ther. 64 1998 123 128
84. E.J. Wang, C.N. Casciano, R.P. Clement, and W.W. Johnson Inhibition of P-glycoprotein transport function by grapefruit juice psoralen Pharm. Res. 18 2001 432 438
85. Y.H. Wang, P.D. Chao, S.L. Hsiu, K.C. Wen, and Y.C. Hou Lethal quercetin-digoxin interaction in pigs Life Sci. 74 2004 1191 1197
86. K.M. Wasan Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems Drug Dev. Ind. Pharm. 27 2001 267 276
87. M. Weiss, and W. Kang P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling J. Pharmacol. Exp. Ther. 300 2002 688 694
88. J. Weiss, S.M. Dormann, M. Martin-Facklam, C.J. Kerpen, N. Ketabi-Kiyanvash, and W.E. Haefeli Inhibition of P-glycoprotein by newer antidepressants J. Pharmacol. Exp. Ther. 305 2003 197 204
89. D.C. Wolf, and S.B. Horwitz P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid Int. J. Cancer 52 1992 141 146
90. D.M. Woodcock, M.E. Linsenmeyer, G. Chojnowski, A.B. Kriegler, V. Nink, L.K. Webster, and W.H. Sawyer Reversal of multidrug resistance by surfactants Brit. J. Cancer 66 1992 62 68
91. C. Woodland, Z. Verjee, E. Giesbrecht, G. Koren, and S. Ito The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers J. Pharmacol. Exp. Ther. 283 1997 39 45
92. R. Xie, M. Hammarlund-Udenaes, A.G. de Boer, and E.C. de Lange The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice Brit. J. Pharmacol. 128 1999 563 568
93. D.K. Yu The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions J. Clin. Pharmacol. 39 1999 1203 1211
94. J. Zong, and G.M. Pollack Morphine antinociception is enhanced in mdr1a gene-deficient mice Pharm. Res. 17 2000 749 753